The government has implemented a 30% trade margin cap on non-scheduled anti-cancer drugs to reduce patient expenses by up to 70%. This regulatory move aims to save households ₹2,500 crore annually. Investors are now assessing the potential impact on hospital chains, as the Supreme Court pushes to extend similar price controls to a wider range of medical devices and consumables.
The Indian government has officially capped trade margins on non-scheduled anti-cancer drugs at 30% of the Maximum Retail Price (MRP). This decision, finalized following the 151st meeting of the National Pharmaceutical Pricing Authority (NPPA), is a direct move to lower the financial burden on patients. Government projections suggest this policy could generate roughly ₹2,500 crore in annual savings for households, with costs for some treatments potentially falling by as much as 70%.
This policy is rooted in evidence of extreme pricing disparities in the supply chain. Before the regulation, data showed that some non-scheduled oncology drugs carried trade mark-ups as high as 700% between initial production and the final patient delivery. By invoking Paragraph 19 of the Drugs (Prices Control) Order, 2013, regulators are targeting these systemic price gaps to improve the affordability of critical care treatments.
For investors, the primary concern is the potential for broader regulatory expansion. The Supreme Court is currently hearing arguments regarding the high cost of medical care and has questioned why margin caps should not apply to a wider spectrum of essential medicines and high-margin hospital consumables, such as cardiac stents and saline drips. This creates a regulatory overhang for private hospital chains, which often rely on non-scheduled medical devices and supplies to support their overall operating margins.
Analysts have noted that if these price controls are extended to a larger list of hospital devices and supplies, private hospital chains could face financial pressure. Some estimates suggest that such a move could impact hospital EBITDA by 1% to 2%. While the pharmaceutical industry has largely taken a cautious but cooperative stance on the oncology-specific measures, healthcare providers have urged regulators to consider the full cost structure of hospital delivery, warning that aggressive caps may affect their ability to manage rising infrastructure and operating expenses.
Investors should track two upcoming milestones. First, the expert committee formed under the Directorate General of Health Services is expected to finalize the specific list of drugs covered by the 30% cap within the next two weeks. Second, the Supreme Court has scheduled the next hearing on the government's broader price-control framework for October 27, 2026. These updates will clarify whether the current policy remains limited to oncology or if the regulatory net will widen across the healthcare sector.